Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH
  • @

Browsing Tag

treatment options

17 posts
RRoche
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Read More

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

  • 2026-09-21
F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to…
NNovartis
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Read More

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

  • 2026-07-05
Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
NNovartis
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Read More

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

  • 2026-07-02
Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Novartis Pharma AG Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Novartis Pharma AG Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs…
NNovartis
Cosentyx PMR Data Puts Novartis Pipeline And Earnings Story In Focus
Read More

Cosentyx PMR Data Puts Novartis Pipeline And Earnings Story In Focus

  • 2026-06-04
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
RRoche
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Read More

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

  • 2026-04-25
F. Hoffmann-La Roche Ltd Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein…
RRoche
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Read More

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

  • 2026-04-21
F. Hoffmann-La Roche Ltd Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein…
RRoche
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Read More

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

  • 2026-04-21
F. Hoffmann-La Roche Ltd Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein…
NNovartis
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones
Read More

Novartis Fabhalta Data Sharpens IgA Nephropathy Outlook And Valuation Case

  • 2026-04-07
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
Switzerland
www.europesays.com